Peptide News
Peptide news, explained
Regulatory changes, new brands and ranking updates across the peptide market, each linked to the full article and its sources.
Get Peptide News by email →Is Retatrutide Legal? FDA Status, Compounding, and Lilly’s Lawsuits (November 2026)
Retatrutide is an investigational Eli Lilly drug that no regulator has approved. FDA says it cannot be used in compounding, and the HHS peptide policy does not cover it. A dated guide to its status, the drug-vs-biologic dispute, Lilly's lawsuits and the safety reports.
Read more →Is TB-500 Legal? Its US Regulatory Status After the HHS Peptide Policy (November 2026)
TB-500 is not FDA-approved and not on the 503A bulks list. Since 30 October 2026, HHS has said it will not act against 503A compounders using TB-500 acetate for subcutaneous or intramuscular injection under ten conditions. What the policy defines as TB-500, the timeline, and what has not changed.
Read more →Does the HHS Peptide Policy Apply in Your State? How State Boards Are Responding (November 2026)
HHS's October 2026 peptide compounding policy is federal enforcement discretion only. It does not bind state boards of pharmacy, medicine or nursing. What NABP told the boards, which states have said what, and the questions to ask before relying on the policy.
Read more →Which Peptides Are Next? FDA’s 2027 Compounding Committee Agenda: GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF
FDA says its Pharmacy Compounding Advisory Committee will meet before the end of February 2027 to discuss five peptide substances for the 503A bulks list. What is on the agenda, what FDA has already said about each, what a vote can and cannot do, and how to follow it.
Read more →USA Peptide Depot (usapeptidedepot.com): New US Research Peptide Supplier (Launched November 2026)
USA Peptide Depot, operated by USAPD LLC, was announced on 4 November 2026 by Peptides Costa Rica as a US-shipped research-use-only peptide supplier. What it says it offers, what its COA database shows, and what we could not verify.
Read more →NextWave Peptides (nextwavepeptides.com): New US Research Peptide Catalog (Launched October 2026)
NextWave Peptides announced its US-based research peptide catalog on 13 October 2026 from Los Angeles. What it says it offers, what its 57-record COA library shows, which labs are named, and what we could not verify.
Read more →HHS’s Peptide Compounding Policy: The 6 Peptides Covered and the 10 Conditions
HHS published its enforcement discretion policy for 503A compounding of BPC-157, TB-500, KPV, MOTS-c, semax and epitalon on 30 October 2026. The covered routes, the 10 conditions, who it applies to, and what it does not change.
Read more →Research-Use-Only vs Compounded vs FDA-Approved Peptides: What Is the Difference?
The same peptide name can be sold three ways: as a research chemical, as a compounded prescription, or as an FDA-approved drug. Who regulates each, what paperwork comes with it, and what the October 2026 HHS policy changed and did not change.
Read more →Is BPC-157 Legal? Its US Regulatory Status After the HHS Policy (November 2026)
BPC-157 is not FDA-approved and not on the 503A bulks list. Since 30 October 2026, HHS has said it will not take enforcement action against 503A compounders using BPC-157 acetate under ten conditions. A dated timeline, what the policy covers, and what has not changed.
Read more →HPLC, Mass Spec, Endotoxin: What the HHS Peptide Testing Standard Asks a COA to Show
The HHS peptide policy includes a testing standard for bulk peptide APIs used in compounding. What each test measures (HPLC assay, mass spec identity, peptide content, endotoxin, residual solvents, TFA), what the COA must state, and how it compares with typical research-market reports.
Read more →503A vs 503B: Who Can Compound Peptides, and Why the HHS Policy Covers Only One
503A pharmacies compound for individual prescriptions; 503B outsourcing facilities register with FDA, follow CGMP and can supply office stock. How each one can (or cannot) use peptide bulk substances, and why the October 2026 HHS peptide policy names only 503A.
Read more →Phases (wearephases.com): New Women-Focused Peptide Telehealth Platform (Launched November 2026)
Phases launched on 3 November 2026 as a US telehealth platform for compounded peptide prescriptions aimed at women. Who operates it, what its site lists, how the prescription process works, and what we could not verify.
Read more →Nuvials (nuvials.com): New Arizona Research Peptide Supplier (Launched November 2026)
Nuvials, LLC launched nuvials.com on 3 November 2026 as a research-use-only peptide supplier that requires a researcher-access application before purchase. What it says it offers, what its COAs show, and what we could not verify.
Read more →How to Verify a Peptide COA: Match the Lot, Report and Laboratory
A step-by-step method for checking a peptide certificate of analysis: match the lot on your vial to the report, confirm the report ID with the issuing lab, read identity, purity and quantity results correctly, and understand what a COA cannot tell you.
Read more →Comparing Peptide Wholesale Programs: Documentation, Lot Traceability and Commercial Terms
How three peptide wholesale programs compare on documented MOQ, pricing basis, lot reservation, lead times, COAs and private-label terms, read from their own pages (October 2026), plus a buyer’s checklist for any program.
Read more →Simple Life Science: New Research Peptide and API Brand (Launched October 2026)
Simple Life Science is a research-use peptide, API and custom-synthesis brand launched in October 2026 by Melex Technologies, the operator of Simple Peptide. What it says it offers, what is visible on its site, and what we could not verify.
Read more →Every item links to a PAL article with its sources and check date. News items are editorial; sponsored content is always labelled.